199 related articles for article (PubMed ID: 33694311)
1. Angiotensin-converting enzyme inhibitors increase anti-fibrotic biomarkers in African Americans with left ventricular hypertrophy.
A Romero C; Mathew S; Wasinski B; Reed B; Brody A; Dawood R; Twiner MJ; McNaughton CD; Fridman R; Flack JM; Carretero OA; Levy PD
J Clin Hypertens (Greenwich); 2021 May; 23(5):1008-1016. PubMed ID: 33694311
[TBL] [Abstract][Full Text] [Related]
2. Abnormalities of the extracellular degradation of collagen type I in essential hypertension.
Laviades C; Varo N; Fernández J; Mayor G; Gil MJ; Monreal I; Díez J
Circulation; 1998 Aug; 98(6):535-40. PubMed ID: 9714110
[TBL] [Abstract][Full Text] [Related]
3. Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension.
Rasoul S; Carretero OA; Peng H; Cavasin MA; Zhuo J; Sanchez-Mendoza A; Brigstock DR; Rhaleb NE
J Hypertens; 2004 Mar; 22(3):593-603. PubMed ID: 15076166
[TBL] [Abstract][Full Text] [Related]
4. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition.
Azizi M; Ezan E; Nicolet L; Grognet JM; Ménard J
Hypertension; 1997 Nov; 30(5):1015-9. PubMed ID: 9369248
[TBL] [Abstract][Full Text] [Related]
5. N-acetyl-seryl-aspartyl-lysyl-proline mediates the anti-fibrotic properties of captopril in unilateral ureteric obstructed BALB/C mice.
Chan GCW; Wu HJ; Chan KW; Yiu WH; Zou A; Huang XR; Lan HY; Lai KN; Tang SCW
Nephrology (Carlton); 2018 Apr; 23(4):297-307. PubMed ID: 28075040
[TBL] [Abstract][Full Text] [Related]
6. Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats.
Peng H; Carretero OA; Raij L; Yang F; Kapke A; Rhaleb NE
Hypertension; 2001 Feb; 37(2 Pt 2):794-800. PubMed ID: 11230375
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertension.
Rhaleb NE; Peng H; Yang XP; Liu YH; Mehta D; Ezan E; Carretero OA
Circulation; 2001 Jun; 103(25):3136-41. PubMed ID: 11425781
[TBL] [Abstract][Full Text] [Related]
8. The Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-Analysis.
Mnguni AT; Engel ME; Borkum MS; Mayosi BM
PLoS One; 2015; 10(12):e0143338. PubMed ID: 26656271
[TBL] [Abstract][Full Text] [Related]
9. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor.
Kohno M; Horio T; Yokokawa K; Yasunari K; Ikeda M; Minami M; Kurihara N; Takeda T
Am J Med; 1995 Mar; 98(3):257-65. PubMed ID: 7872342
[TBL] [Abstract][Full Text] [Related]
10. Left ventricular hypertrophy among black hypertensive patients: focusing on the efficacy of angiotensin converting enzyme inhibitors.
Jaleta GN; Gudina EK; Getinet W
BMC Res Notes; 2014 Jan; 7():45. PubMed ID: 24444396
[TBL] [Abstract][Full Text] [Related]
11. Effects of ACE inhibition versus non-ACE inhibitor antihypertensive treatment on myocardial fibrosis in patients with arterial hypertension. Retrospective analysis of 120 patients with left ventricular endomyocardial biopsies.
Brilla CG; Rupp H; Maisch B
Herz; 2003 Dec; 28(8):744-53. PubMed ID: 14689110
[TBL] [Abstract][Full Text] [Related]
12. Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy.
Rizzoni D; Muiesan ML; Porteri E; Castellano M; Zulli R; Bettoni G; Salvetti M; Monteduro C; Agabiti-Rosei E
J Hypertens; 1997 Feb; 15(2):197-204. PubMed ID: 9469796
[TBL] [Abstract][Full Text] [Related]
13. Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis.
Brilla CG; Matsubara L; Weber KT
Hypertension; 1996 Aug; 28(2):269-75. PubMed ID: 8707393
[TBL] [Abstract][Full Text] [Related]
14. Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension.
Peng H; Carretero OA; Liao TD; Peterson EL; Rhaleb NE
Hypertension; 2007 Mar; 49(3):695-703. PubMed ID: 17283252
[TBL] [Abstract][Full Text] [Related]
15. The effect of combination therapy on regression of left ventricular hypertrophy in cases with hypertension.
Boydak B; Nalbantgil S; Yilmaz H; Zoghi M; Ozerkan F; Nalbantgil I; Onder R
Saudi Med J; 2004 Dec; 25(12):1975-8. PubMed ID: 15711679
[TBL] [Abstract][Full Text] [Related]
16. ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: a randomized clinical trial.
Paoletti E; Cassottana P; Amidone M; Gherzi M; Rolla D; Cannella G
Am J Kidney Dis; 2007 Jul; 50(1):133-42. PubMed ID: 17591533
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme inhibitors: a new mechanism of action.
Peng H; Carretero OA; Vuljaj N; Liao TD; Motivala A; Peterson EL; Rhaleb NE
Circulation; 2005 Oct; 112(16):2436-45. PubMed ID: 16216963
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy.
Li-Saw-Hee FL; Edmunds E; Blann AD; Beevers DG; Lip GY
Int J Cardiol; 2000 Aug; 75(1):43-7. PubMed ID: 11054505
[TBL] [Abstract][Full Text] [Related]
19. The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases.
Kumar N; Yin C
Pharmacol Res; 2018 Aug; 134():268-279. PubMed ID: 29990624
[TBL] [Abstract][Full Text] [Related]
20. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts.
Rhaleb NE; Peng H; Harding P; Tayeh M; LaPointe MC; Carretero OA
Hypertension; 2001 Mar; 37(3):827-32. PubMed ID: 11244003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
